iStock
MediPharm Labs has agreed to acquire VIVO Cannabis today in an all-equity business combination transaction.
The transaction is expected to combine two complementary businesses. Upon the completion of the transaction, existing MediPharm shareholders are expected to own between 65% and 79% of the combined company resulting from the transaction and VIVO shareholders are expected to own between 35% and 21% of the combined company.
The acquisition of VIVO will add established Australian and German medical cannabis brand Beacon Medical, medical cannabis clinic business Harvest Medicine, and a longstanding Canadian medical sales platform Canna Farms Medical
